Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 3500
Single User License Price INR 241150
Corporate User License Price USD 10500
Corporate User License Price INR 723450
Site License Price USD 7000
Site License Price INR 482300
Request a Quote

Report Title

Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2018

Quote Request for License Type
License Type Price  
Single User License USD 3500
Site License USD 7000
Enterprise Wide License USD 10500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2018


Quote Request for License Type
License Type Price  
Single User License USD 3500
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2018

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2018



Executive Summary

Adenosine Receptor A3 (ADORA3)-Pipeline Review, H2 2018

Summary

Adenosine Receptor A3 (ADORA3) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest report Adenosine Receptor A3 (ADORA3)-Pipeline Review, H2 2018, outlays comprehensive information on the Adenosine Receptor A3 (ADORA3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Adenosine Receptor A3 (ADORA3)-The adenosine A3 receptor, also known as ADORA3, is an adenosine receptor. Adenosine A3 receptors are G protein-coupled receptors that mediates a sustained cardioprotective function during cardiac ischemia. It is involved in the inhibition of neutrophil degranulation in neutrophil mediated tissue injury, it mediate both cell proliferation and cell death. A3 adenosine receptor (A3AR) is the only adenosine subtype to be over expressed in inflammatory and cancer cells, thus making it a potential target for therapy.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 1, 7, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Immunology, Oncology, Ophthalmology, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Male Health, Metabolic Disorders, Musculoskeletal Disorders, Respiratory and Toxicology which include indications Glaucoma, Non-Alcoholic Steatohepatitis (NASH), Rheumatoid Arthritis, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Arthritis, Asthma, Atopic Dermatitis (Atopic Eczema), Chemotherapy Induced Pain, Chemotherapy Induced Peripheral Neuropathy, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Diabetic Nephropathy, Erectile Dysfunction, Hepatocellular Carcinoma, Inflammation, Kidney Fibrosis, Melanoma, Neuropathic Pain (Neuralgia), Non Alcoholic Fatty Liver Disease (NAFLD), Ocular Hypertension, Open-Angle Glaucoma, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Psoriasis, Pulmonary Fibrosis and Ulcerative Colitis.

Furthermore, this report also reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 (ADORA3)

- The report reviews Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics and enlists all their major and minor projects

- The report assesses Adenosine Receptor A3 (ADORA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Adenosine Receptor A3 (ADORA3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Adenosine Receptor A3 (ADORA3)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Adenosine Receptor A3 (ADORA3) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Adenosine Receptor A3 (ADORA3)-Overview

Adenosine Receptor A3 (ADORA3)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Adenosine Receptor A3 (ADORA3)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Adenosine Receptor A3 (ADORA3)-Companies Involved in Therapeutics Development

Can-Fite BioPharma Ltd

Future Medicine Co Ltd

Palo BioFarma SL

Adenosine Receptor A3 (ADORA3)-Drug Profiles

ACN-1052-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-602-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Agonize ADORA3 for Chemotherapy Induced Pain-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1103-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1202-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1203-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1301-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1302-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LJ-1888-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LJ-2698-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

namodenoson-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBF-1650-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBF-677-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

piclidenoson-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Adenosine Receptor A3 (ADORA3)-Dormant Products

Adenosine Receptor A3 (ADORA3)-Discontinued Products

Adenosine Receptor A3 (ADORA3)-Product Development Milestones

Featured News & Press Releases

Sep 04, 2018: Top line results of the Namodenoson phase II advanced liver cancer trial expected by end of year

Aug 23, 2018: Can-Fite enrolls first patient in Phase III Comfort trial for psoriasis

Jul 17, 2018: Can-Fite Granted Australian and Chinese Patents for Erectile Dysfunction Drug

Jul 02, 2018: Drugs with Mechanism of Action Utilized by Namodenoson Are Recommended by Leading U.S. Researchers to Be Developed to Combat Liver Cancer

Jun 19, 2018: Can-Fite Updates on Status of Phase II Advanced Liver Cancer Trial

Jun 11, 2018: Can-Fite Reports on New Pre-Clinical Developments with Its NASH Drug Namodenoson

Jun 11, 2018: Can-Fite Reports on New Pre-Clinical Developments with Its NASH Drug Namodenoson

Apr 25, 2018: Can-Fite's Piclidenoson Mechanism of Action in Psoriasis Published in 'Journal of Immunology Research'

Apr 09, 2018: Can-Fite to Present the Anti-Inflammatory and Anti-Fibrogenic Effects of Namodenoson in NAFLD/NASH Pre-clinical Studies at the 2018 International Liver Congress of the European Association for the Study of the Liver (EASL)

Mar 14, 2018: Can-Fite to Present at the NASH 2nd Annual H.C. Wainwright Investor Conference

Mar 06, 2018: Can-Fite to Provide Update on its Lead Drug Candidate Piclidenoson in NASH at the 30th Annual ROTH Conference

Mar 06, 2018: Can-Fite to Provide Update on Liver Drug Namodenoson at the 30th Annual ROTH Conference

Feb 28, 2018: Can Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson

Feb 22, 2018: Can Fite Announces the Submission of Safety Reports for Piclidenoson to FDA and other Regulatory Authorities Showing Favorable Safety Profile

Feb 22, 2018: Can Fite Announces the Submission of Safety Reports for Namodenoson to FDA and other Regulatory Authorities

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Can-Fite BioPharma Ltd, H2 2018

Pipeline by Future Medicine Co Ltd, H2 2018

Pipeline by Palo BioFarma SL, H2 2018

Dormant Products, H2 2018

Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Can-Fite BioPharma Ltd

Future Medicine Co Ltd

Palo BioFarma SL

Adenosine Receptor A3 (ADORA3) Therapeutic Products under Development, Key Players in Adenosine Receptor A3 (ADORA3) Therapeutics, Adenosine Receptor A3 (ADORA3) Pipeline Overview, Adenosine Receptor A3 (ADORA3) Pipeline, Adenosine Receptor A3 (ADORA3) Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person